Yayoi Tada

60PUBLICATIONS
69CO-AUTHORS
PharmacogenomicsClinical pharmacology and therapeuticsPharmaceutical delivery technologiesAllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (60)

|Aug 15, 2026
Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

|Aug 06, 2026
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

|Aug 02, 2026
Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study.

|Jul 27, 2026
Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.

|Mar 08, 2026
A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.

Thalita Bastos, Makoto Ito, Masahiro Kamata

|Dec 31, 2025
Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).

Akimichi Morita, Yayoi Tada, Yuichiro Tsunemi

Pageof 10

Frequent Collaborators

31 joint publications

Masahiro Kamata

12 joint publications

Akimichi Morita

11 joint publications

Yukari Okubo

8 joint publications

Shinichi Imafuku